CION Ameerpet
Lymphoma is one of the more common cancers of the immune system — yet it is often highly treatable and, for many, curable. This guide explains lymphoma incidence in India and worldwide, how many people get lymphoma, and who is most at risk.
Lymphoma is a cancer of the lymphatic system — the network of lymph nodes, vessels and lymphoid tissue that forms part of the body's immune defences. It is not a single disease but a family of many subtypes, split into two broad groups: the much larger non-Hodgkin lymphoma (NHL) and the rarer Hodgkin lymphoma (HL). For the wider picture, see our Lymphoma hub.
So how common is lymphoma? Non-Hodgkin lymphoma is among the ten most frequently diagnosed cancers worldwide, while Hodgkin lymphoma is considerably rarer. Taken together, the lymphomas account for a few per cent of all cancer diagnoses — common enough that any large cancer centre sees them routinely, yet far less common than breast, lung or bowel cancer. Understanding how many people get lymphoma helps put a new diagnosis into perspective, but it says nothing about any one person's outlook.
This page walks through lymphoma incidence in India and globally, who is most at risk by age and type, how lymphoma compares with leukaemia, and what "common" really means for outcomes. If you have a persistent swollen node or other symptoms, you can book a free consultation or explore lymphoma treatment in Hyderabad.
Non-Hodgkin lymphoma consistently ranks among the top ten most common cancers worldwide, with hundreds of thousands of new cases recorded every year — the great majority NHL rather than the rarer Hodgkin lymphoma. Incidence rises with age for NHL, while Hodgkin lymphoma has a distinctive pattern that peaks in young adults. (Source: global cancer incidence estimates, consistent with NCCN and ESMO lymphoma guidance.)
Because lymphoma is really many diseases, "how common" depends on which type you mean. This general comparison shows why non-Hodgkin lymphoma drives most of the totals.
| Group | Relative Frequency | Typical Age Pattern | General Outlook |
|---|---|---|---|
| Non-Hodgkin lymphoma (NHL) | The large majority of lymphoma cases; among the top ten cancers worldwide | More common with increasing age; most diagnoses in older adults | Highly variable by subtype; the common DLBCL subtype is cured in many people |
| Hodgkin lymphoma (HL) | Much rarer — a small fraction of all lymphomas | Peaks in young adults, with a second rise later in life | Among the most curable cancers, with high long-term survival |
This table is a general guide; exact frequencies and outcomes vary by individual, subtype, stage and data source. Figures are consistent with published series and NCCN/ESMO guidance rather than CION-specific statistics.
Incidence describes how many new cases occur in a population each year. In India it is lower than in many Western countries, but is increasingly recorded as diagnosis and cancer registries improve.
National Cancer Registry Programme data place non-Hodgkin lymphoma among the leading cancers in men, while Hodgkin lymphoma stays uncommon. Reported lymphoma incidence in India sits broadly at a few new cases per 100,000 people each year, with NHL several times more common than HL. Numbers vary by region and registry completeness.
NHL becomes more common with age and is diagnosed most often in older adults; HL peaks in young adults and again later in life. Men are slightly more affected than women overall. For a closer look, see at what age does lymphoma occur?
A weakened immune system, certain long-standing infections, some autoimmune conditions and a family history of lymphoma can all raise risk — but most people with these never develop lymphoma, and many patients have no identifiable risk factor at all.
Recorded NHL rates have risen over decades, partly reflecting an ageing population and better detection rather than only a true increase. HL rates have stayed relatively stable. Awareness of the early signs of lymphoma supports earlier diagnosis.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you have a persistent swollen node, want to understand what a lymphoma diagnosis means, or need a second opinion before treatment, CION's haematology & oncology team is here.
Lymphoma and leukaemia are both cancers of the blood and immune system, and people often ask how they compare in frequency. In most populations, lymphomas as a group are diagnosed somewhat more often than leukaemias, largely because non-Hodgkin lymphoma is so common. The two can overlap — some conditions carry features of both.
The key difference is where the cancer mainly shows up. Lymphoma tends to form solid collections in lymph nodes and lymphoid tissue, while leukaemia mainly involves the blood and bone marrow. Both are managed by haematology and medical oncology teams, and both are investigated with blood tests, imaging and often a bone-marrow examination.
If a relative has been told they have "a blood cancer" and it is unclear which, a specialist review can confirm the exact diagnosis. You may also find our sibling guides useful — how fast does lymphoma grow? and can a blood test detect lymphoma?
How common a cancer is tells you nothing about how dangerous it is for one person. Many lymphomas are among the most treatable — and frequently curable — of all cancers. Outlook depends on the exact subtype, stage, age and general health, not on how often the disease occurs.
Published series report that Hodgkin lymphoma has long-term survival of roughly 80–90%, and the common non-Hodgkin subtype diffuse large B-cell lymphoma is cured in around 60–70% of people (NCCN and ESMO). These are population figures — outcomes vary by individual, stage and subtype, and your own outlook can only be judged after the exact diagnosis is confirmed. To understand what numbers mean for you, see lymphoma life expectancy and is stage 4 lymphoma curable?
CION delivers the mainstays of lymphoma care directly: chemotherapy, immunotherapy with monoclonal antibodies (such as anti-CD20 antibody therapy), radiation therapy (IMRT), biopsy and bone-marrow assessment, watch-and-wait monitoring for selected indolent lymphomas, and survivorship care. Where a stem-cell transplant or CAR-T cell therapy is needed, this is coordinated through accredited partner facilities. Every case is reviewed by a multidisciplinary tumour board before the plan is set. Specific drug regimens are discussed on the lymphoma treatment page, and questions like how many cycles of chemotherapy will I need? are answered there.
Being a "common" cancer and being a dangerous one are not the same thing. Hodgkin lymphoma — one of the rarer lymphomas — is also one of the most curable cancers, with published long-term survival around 80–90%, while the common non-Hodgkin subtype DLBCL is cured in roughly 60–70% of people. Figures vary by individual, stage and subtype. (Source: published clinical series, consistent with NCCN and ESMO lymphoma guidelines.)
This page is part of a series answering the questions people most often ask about lymphoma. Browse the full set, or start with the Lymphoma hub, Lymphoma Treatment in Hyderabad, the best lymphoma doctors in Hyderabad, or the best lymphoma hospital in Hyderabad.
Lymphoma is common enough to be worth knowing about, but a swollen node is usually not cancer — most are caused by ordinary infections. It is worth a specialist review when a symptom is new, persistent and unexplained:
CION offers a dedicated, free written second-opinion service on your biopsy and PET-CT report, with transparent costs explained up front — a plan built around healing, not billing. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's haematology & oncology team — especially valuable before starting treatment or if the subtype is still being confirmed.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Lymphoma is among the more common cancers worldwide, but it is far less common than cancers such as breast, lung or bowel cancer. Globally, non-Hodgkin lymphoma (NHL) is the most frequent type and sits within the top ten cancers overall, while Hodgkin lymphoma (HL) is considerably rarer. Together the lymphomas make up a few per cent of all cancer diagnoses. Put another way, lymphoma is common enough that most large cancer centres see it regularly, yet uncommon enough that many people have never met someone with it. Because it is a treatable — and often curable — group of cancers, understanding how frequently it occurs helps put a new diagnosis into perspective. If you have concerns, you can book a free consultation with a CION haematologist.
In India, lymphoma incidence is lower than in many Western countries but is being recorded more often as diagnosis and cancer registries improve. National Cancer Registry Programme data place non-Hodgkin lymphoma among the leading cancers in men, while Hodgkin lymphoma remains uncommon. Reported figures for lymphoma incidence in India are broadly in the range of a few new cases per 100,000 people per year, and NHL is several times more common than HL. Actual numbers vary by region, age and how completely cases are registered, so these should be read as estimates rather than exact counts. For clinical facts we follow NCCN and ESMO guidance, and figures always vary by individual and by data source.
Worldwide, hundreds of thousands of people are diagnosed with lymphoma every year, the large majority of them with non-Hodgkin lymphoma rather than Hodgkin lymphoma. Because lymphoma is really a family of many subtypes, "how many people get lymphoma" depends on which types are counted. NHL accounts for the bulk of cases; HL is much less frequent but tends to affect younger adults. Exact annual counts differ between global bodies, national registries and individual hospitals, and they change as populations age and detection improves. Rather than focusing on a single number, it is more useful to know that lymphoma is a well-studied, often highly treatable cancer with clear, guideline-based care pathways.
Recorded rates of non-Hodgkin lymphoma have risen over past decades in many countries, though part of that rise reflects an ageing population, better imaging, more accurate biopsy diagnosis and more complete cancer registries — not only a true increase in disease. Some risk factors, such as certain chronic infections, autoimmune conditions and immune suppression, are also relevant. Hodgkin lymphoma rates have stayed relatively stable. Because lymphoma is a diverse group, trends differ by subtype and region. The practical message is not alarm but awareness: knowing the early signs of lymphoma and acting on persistent, unexplained symptoms leads to earlier diagnosis, which usually means more treatment options.
Lymphoma can occur at any age, but the pattern differs by type. Non-Hodgkin lymphoma becomes more common with increasing age and is diagnosed most often in older adults, while Hodgkin lymphoma has a distinctive pattern with peaks in young adults and again in later life. Men are slightly more likely to develop lymphoma than women overall. Other factors that can raise risk include a weakened immune system, certain long-standing infections, some autoimmune diseases and a family history of lymphoma — though most people with these factors never develop it, and many patients have no identifiable risk factor at all. For a closer look at age patterns, see at what age does lymphoma occur?
Lymphoma and leukaemia are both cancers of the blood and immune system, and together they account for a meaningful share of all cancers. In most populations, lymphomas as a group are diagnosed somewhat more often than leukaemias, largely because non-Hodgkin lymphoma is so common. The two overlap: some conditions have features of both. The key difference is where the cancer mainly shows up — lymphoma tends to form solid collections in lymph nodes and lymphoid tissue, whereas leukaemia mainly involves the blood and bone marrow. Both are managed by haematology and medical oncology teams. If you are unsure which you or a relative has, a specialist review can clarify the exact diagnosis.
How common a cancer is does not tell you how dangerous it is for any one person. Many lymphomas are among the most treatable — and frequently curable — of all cancers. Published series report that Hodgkin lymphoma has long-term survival of roughly 80–90%, and the common non-Hodgkin subtype diffuse large B-cell lymphoma is cured in around 60–70% of people, though figures vary by individual, stage and subtype (NCCN and ESMO). Outlook depends on the exact type, stage, age and general health, not on how often the disease occurs. That is why an accurate diagnosis and a personalised, guideline-based plan matter far more than population statistics. CION delivers that care directly — you can explore lymphoma treatment in Hyderabad.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.